Friday, July 10, 2026

Drug profile · INN

serelaxin

serelaxin (REASANZ) is a relaxin receptor 2 activator.

EMA: refused Cardiovascular system (C01) C01DX21
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — serelaxin
Class
Cardiovascular system (C01)
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

serelaxin (REASANZ) is a relaxin receptor 2 activator.

Key facts

INN serelaxin
Brand REASANZ
Mechanism Relaxin receptor 2 activator
Target Relaxin receptor 1
Therapeutic class Cardiovascular system (C01)
ATC code C01DX21

Mechanism of action

Relaxin receptor 2 activator

Primary target: Relaxin receptor 1

Approval history

Authority Status Date
EMA refused

Pipeline programs

  1. Serelaxin Phase 2 · Novartis India · Acute Heart Failure

Related & competitor drugs

  1. alirocumab Cardiovascular system (C10)
  2. aliskiren Cardiovascular system (C09)
  3. azilsartan medoxomil Cardiovascular system (C09)
  4. bempedoic acid Cardiovascular system (C10)
  5. bosentan Cardiovascular system (C02)
  6. dofetilide Cardiovascular system (C01)

Frequently asked questions

What is serelaxin?

serelaxin (REASANZ) is a relaxin receptor 2 activator.

What is the brand name for serelaxin?

REASANZ is a marketed brand name for serelaxin. Check FDA Drugs@FDA for the current US label holder and prescribing information.